Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature

Clinical Sarcoma Research

Ian Judson²  Helena M Earl¹  Cyril Fisher⁴  Gail Horan³  Omar Al-Muderis²  Charlotte Benson²  Helen M Hatcher³  Han Hsi Wong³ 

[1] University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Hills Road, Cambridge CB2 0QQ, UK;Sarcoma Unit, The Royal Marsden, Fulham Road, London SW3 6JJ, UK;Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK;Department of Histopathology, The Royal Marsden, Fulham Road, London SW3 6JJ, UK

关键词: Treatment;    Survival;    Prognosis;    Sarcoma;    Desmoplastic small round cell tumour;   

Others  :  861351
DOI  :  10.1186/2045-3329-3-14

 received in 2013-10-03, accepted in 2013-11-22,  发布年份 2013

【 摘 要 】

Background

Desmoplastic small round cell tumour (DSRCT) is a rare but frequently fatal sarcoma, and many of its characteristics still require further clarification.

Methods

We retrospectively analysed 41 patients treated at or referred to two regional referral centres in the UK between 1991 and 2012. A review of the current literature was also performed.

Results

The median age of presentation was 27 years (range 16 to 45 years), with a male-to-female ratio of 3:1. Ninety percent of patients had disease in the abdomen. The median size of the presenting tumour was 13 cm (range 3.5 to 23 cm), and 80% had metastatic disease at diagnosis, mainly in the liver (33%) and lungs (21%). Time-to-progression (TTP) was 3.9, 2.3 and 1.1 months after first-, second- and third-line chemotherapy, respectively. First-line treatment with VIDE chemotherapy appeared to confer the longest TTP (median 14.6 months). Ifosfamide and doxorubicin resulted in TTP of >3.8 months when used in any-line setting. Eleven patients received targeted agents as part of a clinical trial. After a median follow-up of 14 months, the overall median survival (MS) was 16 months. There was no difference in MS with regards to age, gender, or size of the presenting tumour. Patients with extra-abdominal disease survived longer compared to those with tumours in the abdomen (all still alive vs MS of 15 months; P = 0.0246). Patients with non-metastatic intra-abdominal disease who underwent surgery had an MS of 47 months (16 months for those who did not have surgery; P = 0.0235). Radiotherapy for locoregional control in patients with metastatic intra-abdominal DSRCT was associated with longer survival (MS of 47 vs 14 months; P = 0.0147).

Conclusions

DSRCT is a rare but often fatal disease that mainly affects younger male patients. Those with intra-abdominal DSRCT have a poorer prognosis, although surgical resection for localised disease and radiotherapy in the metastatic setting are associated with improved survival. A patient’s age, gender and size of presenting tumour do not have prognostic significance.

【 授权许可】

   
2013 Wong et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Gerald WL, Ladanyi M, de Alava E, Cuatrecasas M, Kushner BH, LaQuaglia MP, Rosai J: Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol 1998, 16:3028-3036.
• [2]Gerald WL, Rosai J: Case 2. Desmoplastic small cell tumor with divergent differentiation. Pediatr Pathol 1989, 9:177-183.
• [3]Chang F: Desmoplastic small round cell tumors: cytologic, histologic, and immunohistochemical features. Arch Pathol Lab Med 2006, 130:728-732.
• [4]Ladanyi M, Gerald W: Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994, 54:2837-2840.
• [5]Kretschmar CS, Colbach C, Bhan I, Crombleholme TM: Desmoplastic small cell tumor: a report of three cases and a review of the literature. J Pediatr Hematol Oncol 1996, 18:293-298.
• [6]Dufresne A, Cassier P, Couraud L, Marec-Bérard P, Meeus P, Alberti L, Blay J-Y: Desmoplastic small round cell tumor: current management and recent findings. Sarcoma 2012, 2012:714986.
• [7]Schwarz RE, Gerald WL, Kushner BH, Coit DG, Brennan MF, La Quaglia MP: Desmoplastic small round cell tumors: prognostic indicators and results of surgical management. Ann Surg Oncol 1998, 5:416-422.
• [8]Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP: Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg 2005, 40:251-255.
• [9]Hassan I, Shyyan R, Donohue JH, Edmonson JH, Gunderson LL, Moir CR, Arndt CAS, Nascimento AG, Que FG: Intraabdominal desmoplastic small round cell tumors: a diagnostic and therapeutic challenge. Cancer 2005, 104:1264-1270.
• [10]Subbiah V, Viny AD, Anderson PM, Hayes-Jordan AA, Qiao W, Benjamin RS, Maki RG, Ludwig JA: Optimizing the therapy of desmoplastic small round cell tumor: combined experience from the two major cancer centers. J Clin Oncol 2012, 30:10021.
• [11]Farhat F, Culine S, Lhommé C, Duvillard P, Soulié P, Michel G, Terrier-Lacombe MJ, Théodore C, Schreinerova M, Droz JP: Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Cancer 1996, 77:1363-1366.
• [12]Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF, Steinherz PG, Gerald WL: Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996, 14:1526-1531.
• [13]Bertuzzi A, Castagna L, Nozza A, Quagliuolo V, Siracusano L, Balzarotti M, Compasso S, Alloisio M, Soto Parra H, Santoro A: High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002, 20:2181-2188.
• [14]Bertuzzi A, Castagna L, Quagliuolo V, Ginanni V, Compasso S, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Sarina B, Parra HS, Santoro A: Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour. Br J Cancer 2003, 89:1159-1161.
• [15]Cook RJ, Wang Z, Arora M, Lazarus HM, Kasow KA, Champagne MA, Saber W, van Besien KM, Hale GA, Copelan EA, Elmongy M, Ueno NT, Horn BN, Slavin S, Bishop MR, Stadtmauer EA: Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transpl 2012, 47:1455-1458.
• [16]Rosoff PM, Bayliff S: Successful clinical response to irinotecan in desmoplastic round blue cell tumor. Med Pediatr Oncol 1999, 33:500-503.
• [17]Ferrari A, Grosso F, Stacchiotti S, Meazza C, Zaffignani E, Marchianò A, Casanova M: Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor. Pediatr Blood Cancer 2007, 49:864-866.
• [18]Hendifar AE, Chawla SP, Leahy MG, Italiano A, Patel S, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Demetri GD, Hayward L, White J, Gouw LG, De Miguel B, Lardelli P, Soto A, Nieto A, Blay J-Y: Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS). J Clin Oncol 2013, 31:10517.
• [19]Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E: A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer 2012, 59:865-869.
• [20]López-González A, Cantos B, Tejerina E, Provencio M: Activity of trabectidin in desmoplastic small round cell tumor. Med Oncol 2011, 28(Suppl 1):S644-S646.
• [21]Hayes-Jordan A, Anderson P, Curley S, Herzog C, Lally KP, Green HL, Hunt K, Mansfield P: Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor. J Pediatr Surg 2007, 42:E29-E32.
• [22]Aguilera D, Hayes-Jordan A, Anderson P, Woo S, Pearson M, Green H: Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumor. Sarcoma 2008, 2008:261589.
• [23]Hayes-Jordan A, Green H, Fitzgerald N, Xiao L, Anderson P: Novel treatment for desmoplastic small round cell tumor: hyperthermic intraperitoneal perfusion. J Pediatr Surg 2010, 45:1000-1006.
• [24]Goodman KA, Wolden SL, La Quaglia MP, Kushner BH: Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumor. Int J Radiat Oncol Biol Phys 2002, 54:170-176.
• [25]Pinnix CC, Fontanilla HP, Hayes-Jordan A, Subbiah V, Bilton SD, Chang EL, Grosshans DR, McAleer MF, Sulman EP, Woo SY, Anderson P, Green HL, Mahajan A: Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery. Int J Radiat Oncol Biol Phys 2012, 83:317-326.
• [26]Desai NB, Stein NF, LaQuaglia MP, Alektiar KM, Kushner BH, Modak S, Magnan HM, Goodman K, Wolden SL: Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience. Int J Radiat Oncol Biol Phys 2013, 85:e67-e72.
• [27]Italiano A, Kind M, Cioffi A, Maki RG, Bui B: Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. Target Oncol 2013, 8:211-213.
• [28]Thijs AMJ, van der Graaf WTA, van Herpen CML: Temsirolimus for metastatic desmoplastic small round cell tumor. Pediatr Blood Cancer 2010, 55:1431-1432.
• [29]Fine RL, Shah SS, Moulton TA, Yu I-R, Fogelman DR, Richardson M, Burris HA, Samuels BL, Assanasen C, Gorroochurn P, Hibshoosh H, Orjuela M, Garvin J, Goldman FD, Dubovsky D, Walterhouse D, Halligan G: Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy. Cancer Chemother Pharmacol 2007, 59:429-437.
• [30]Karnieli E, Werner H, Rauscher FJ, Benjamin LE, LeRoith D: The IGF-I receptor gene promoter is a molecular target for the Ewing’s sarcoma-Wilms’ tumor 1 fusion protein. J Biol Chem 1996, 271:19304-19309.
• [31]Finkeltov I, Kuhn S, Glaser T, Idelman G, Wright JJ, Roberts CT, Werner H: Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein. Oncogene 2002, 21:1890-1898.
• [32]Werner H, Idelman G, Rubinstein M, Pattee P, Nagalla SR, Roberts CT: A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Cancer Lett 2007, 247:84-90.
• [33]Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A: Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012, 30:1849-1856.
• [34]Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors. Clin Cancer Res 2012, 18:2625-2631.
• [35]Modak S, Gerald W, Cheung N-K V: Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol 2002, 39:547-551.
• [36]Yang RK, Sondel PM: Anti-GD2 strategy in the treatment of neuroblastoma. Drugs Futur 2010, 35:665.
• [37]Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
• [38]Schildhaus H-U, Riegel R, Hartmann W, Steiner S, Wardelmann E, Merkelbach-Bruse S, Tanaka S, Sonobe H, Schüle R, Buettner R, Kirfel J: Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors. Hum Pathol 2011, 42:1667-1675.